Speakers: 

Evan Liddington, PharmD, PGY2 Hematology/Oncology Resident - has nothing to disclose.

Michael Carcella, DO, PGY4 Hematology/Oncology Fellow - has nothing to disclose.

Moderator: 

Tristan Maiers, PharmD, BCOP, PGY2 Oncology Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Obtain a basic understanding of the work-up and testing used in the diagnostic evaluation of DLBCL
• Discuss the staging system for DLBCL
• Review risk-prediction scoring for general prognostics as well as CNS involvement
• Review accepted frontline treatment regimens for DLBCL NOS
• Discuss specific pharmacotherapeutic agents, their mechanisms, and adverse events
• Discuss pharmacotherapeutic agents used in the management or prevention of CNS disease

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP; Rajiv Panikkar, MD; Michele Long, BSN; Jaime Weeder, NP and Christopher Kashi, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None